
Metabolic
Tirzepatide 20mg
Dual GLP-1 / GIP agonist
Overview
Dual GLP-1 / GIP agonist
Tirzepatide is a synthetic peptide with agonist activity at both the GIP and GLP-1 receptors. Supplied lyophilized as a reference reagent for in-vitro study of dual incretin receptor signaling.
- Fill: 20 mg / vial
- Pack: 1 vial · 20 mg total
- Purity: ≥99%
For in-vitro laboratory research use only. Not for human or animal consumption, medical, diagnostic or therapeutic use.
Receptor pharmacology
Slows gastric emptying, enhances central satiety signaling, and increases glucose-dependent insulin secretion via dual incretin receptor activation. GIP potentiation is thought to improve adipose insulin sensitivity beyond GLP-1 alone.
Laboratory handling
Research use disclaimer
Sacred Peptides does not provide dosing recommendations for human use. Tirzepatide 20mg is supplied for in-vitro laboratory research only. Any concentration ranges referenced on this page or in cited studies describe the parameters used in that research and are not instructions.
- Not a drug. Not approved by Health Canada or the FDA for human use.
- Not intended to diagnose, treat, cure, or prevent any disease.
- Not for use in humans, pregnant or nursing individuals, or animals outside a controlled research setting.
- Handling, storage, and disposal are the responsibility of a qualified researcher.